baber/WOPTO huggingface dataset:
Patent NZ-571465-A (NZ)
Title: Compositions and methods for reducing cellular fat and for predicting cardiac toxicity and upon treatment with tyrosine kinase inhibitors
Inventor: BACUS SARAH S
IPC: C12P13/22
Filed: 2007-02-27
Abstract: Provided is a method for predicting cardiac toxicity in a patient selected for treatment with a tyrosine kinase inhibitor, said method comprising: identifying a cell population or serum sample obtained from a patient selected for treatment with the tyrosine kinase inhibitor, screening the cell population or serum sample for a fatty acid oxidation disorder; and determining whether a fatty acid oxidation disorder exists in the cell population or serum sample, whereby the presence of a fatty acid oxidation disorder in the cell population or serum sample predicts that the patient will likely exhibit cardiac toxicity in response to treatment with the tyrosine kinase inhibitor, for example erbB inhibitor or trastuzumab.
Patent NZ-572519-A (NZ)
Title: Recombinant host for producing l-asparaginase ii
Inventor: FILPULA DAVID R
IPC: A61K38/46
Filed: 2007-06-08
Abstract: Disclosed is a recombinant Escherichia coli host cell for producing an Escherichia coli L-asparaginase II enzyme, comprising an Escherichia coli chromosome and at least one copy of a recombinant extrachromosomal vector, wherein the recombinant extrachromosomal vector encodes a subunit of the L-asparaginase II enzyme, wherein the host cell chromosome also encodes the same subunit of the L-asparaginase II enzyme, and wherein the host chromosome does not encode any other isoform of L-asparaginase II, wherein the encoded L-asparaginase II subunit comprises SEQ ID NO: 1; and the recombinant extrachromosomal vector comprises a DNA molecule encoding the L-asparaginase protein II subunit comprising SEQ ID NO: 2.
Patent NZ-575111-A (NZ)
Title: 2-methylene-(20r,25s)-19,27-dinor-(22e)-vitamin d analogs
Inventor: DELUCA HECTOR F
IPC: A61K31/59
Filed: 2007-09-25
Abstract: Disclosed is a compound having the formula (I) e.g. 2-methylene-(20R,25S)-19,27-dinor-(22E)-1alpha,25-dihydroxyvitamin D3 where X1, X2 and X3, which may be the same or different, are each selected from hydrogen or a hydroxy-protecting group selected from the group consisting of alkoxycarbonyl, acyl, alkylsilyl, a alkylarylsilyl and alkoxyalkyl groups for treating psoriasis, a disease selected from the group consisting of leukemia, colon cancer, breast cancer, skin cancer and prostate cancer, an autoimmune disease selected from the group consisting of multiple sclerosis, lupus, diabetes mellitus, host versus graft rejection, and rejection of organ transplant, an inflammatory disease selected from the group consisting of rheumatoid arthritis, asthma, and inflammatory bowel disease, a skin condition selected from the group consisting of wrinkles, lack of adequate skin firmness, lack of adequate dermal hydration and insufficient sebum secretion, renal osteodystrophy or for treating or preventing obesity, inhibiting adipocyte differentiation, inhibiting SCD-1 gene transcription, and/or reducing body fat in an animal.
Patent NZ-575422-A (NZ)
Title: Solid dosage form of olmesartan medoxomil and amlodipine with reduced amounts of impurities and reducing sugars
Inventor: BAUER WOLFGANG
IPC: A61K31/4178
Filed: 2007-10-12
Abstract: Disclosed is a solid dosage form comprising olmesartan, medoxomil and amlodipine or a pharmacologically acceptable salt thereof, wherein said solid dosage form is substantially free of reducing sugars. In particular the composistions have small amounts of the impurities 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-imidazol-5-carboxylic acid and 3-ethyl-5-methyl-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methylpyridine-3,5-dicarboxylate. Also disclosed is the method of treating hypertension in a warm-blooded non-human animal and the use of a solid dosage form in the manufacture of a medicament for the treatment or prophylaxis of hypertension.
Patent NZ-575680-A (NZ)
Title: Restraint of vertebrate animals
Inventor: LINES LANCELOT HAMILTON
IPC: A01K15/04
Filed: 2009-03-19
Abstract: A method of temporarily paralysing the rear of a sheep by placing electrodes on opposite sides of a bare area of the groin of the sheep and then applying an electric current. The electric current passes through the leg muscles on either side of the bare area of the groin of the sheep and also through the rump of the sheep thereby inducing a temporary paralysis in the rear of the sheep.
Patent NZ-582260-A (NZ)
Title: Aqueous composition for inactivating sporulated and/or non-sporulated coccidian parasites
Inventor: VERKAAR EDWARD
IPC: A01N59/00
Filed: 2007-08-16
Abstract: Disclosed herein is an aqueous composition for inactivating sporulated and/or non-sporulated Coccidia parasites, wherein the composition includes, prior to the dilution of water; a) 15 to 115ppm chlorine dioxide and 10-25wt-% of an anionic surfactant having one or more C6 to C18 alkyl groups and one or more aryl groups, b) an acid solution including i) 1 to 5wt-% of a weak carboxylic acid and ii) 2 to 10wt-% phosphoric acid, and wherein the final composition has been diluted at a ratio, composition to water, or between 1:10 to 1:1000. Also disclosed is a method for preparing the aqueous composition as described above, by combining a) a chlorite part including an alkali metal chlorite, and b) an acid solution including i) 1 to 5wt-% of a weak carboxylic acid and ii) 2 to 10wt-% phosphoric acid, c) 10 to 25wt-% of the anionic surfactant, and subsequently diluting the composition at a ratio, composition to water, between 1:10 to 1:1000.
Patent NZ-584371-A (NZ)
Title: Multiple-function contactless biometric identification and authentication system
Inventor: COUROUBLE BENOIT
IPC: H04W4/80
Filed: 2008-10-17
Abstract: Disclosed is an authentication system including a plurality of authentication devices and a terminal. The terminal includes biometric means arranged to generate biometric information about a user and wireless communication means arranged to transmit this information to each personal authentication device. Each personal authentication device includes a memory arranged to store biometric data on the holder of the personal authentication device, a plurality of applications and a list of these applications. Each personal authentication device further includes processing means arranged to compare biometric information to the biometric data to perform an authentication of the user and wireless communication means arranged to transmit to the terminal positive authentication data in case of a positive comparison between the biometric information and stored biometric data. The terminal is arranged to open only a transactional section with each personal device having transmitted positive authentication data. This transactional section is used to request the list of applications of each personal device with which a transactional session has been opened and to carry out a simultaneous selection of a unique personal device and a unique application to perform a transaction. This selection is done by eliminating applications from the list which the terminal does not recognise and/or applying rules of priority in the terminal or the list of applications and/or selecting the unique personal device and application through an action of the user.
Patent NZ-586516-A (NZ)
Title: Pharmaceutical composition comprising a reduced level of diketopiperazine
Inventor: BAR-OR DAVID
IPC: A61K38/00
Filed: 2004-05-14
Abstract: Disclosed is an improved pharmaceutical composition comprising a protein or peptide, wherein the composition also comprises a diketopiperazine derived from the protein or peptide, the improvement being that at least a portion of the diketopiperazine derived from the protein or peptide has been removed from the composition, wherein the protein or peptide is an albumin, an immunoglobulin and/or an erythropoietin.
Patent NZ-587463-A (NZ)
Title: Optical fiber cable with a slotted core in which 2 or more reinforcing members are placed
Inventor: OSATO KEN
IPC: G02B6/44
Filed: 2009-02-18
Abstract: An optical fibre cable 1 having an axis, comprises a slotted core 7 elongated along the axis that includes a slot 11 running in parallel with the axis and a groove 5 accessible through the slot 11, one or more optical fibres 3 placed in the groove 5, a sheath 9 enclosing the slotted core 7 and the optical fibres 3, and a bonding portion 19 where the slotted core 7 is bonded with the sheath 9. The bonding portion 19 ranges over the slotted core 7 in parallel with the axis opposite to the slot of the core. The cable 1 further comprises two or more strength members 17 embedded in the slotted core, the strength members 17 running in parallel with the axis and aligned in a plane that includes the axis.
Patent NZ-588791-A (NZ)
Title: Anti-flt3 antibodies
Inventor: LI YIWEN
IPC: C12N5/10
Filed: 2009-05-28
Abstract: Disclosed is an antibody comprising a CDRH1 having the sequence SYYMH (SEQ ID NO:2), a CDRH2 having the sequence IINPSGGSTSYAQKFQG (SEQ ID NO:3), a CDRH3 having the sequence GVGAHDAFDI (SEQ· ID NO:4), a CDRL1 having the sequence RSSQSLLHSNGNNYLD (SEQ ID NO:6), a CDRL2 having the sequence LGSNRAS (SEQ ID NO:8), and a CDRL3 having the sequence MQGTHP AIS (SEQ ID NO:9).
Patent NZ-589151-A (NZ)
Title: Systems and methods for safe medicament transport
Inventor: GARFIELD JARED
IPC: A61J1/20
Filed: 2009-05-14
Abstract: Disclosed is a medicament transport system to allow safer delivery of potentially toxic medicines contained in a vial. The medicament transport system comprises a syringe adapter assembly fluidly connectable to a first container. The syringe adapter assembly includes a syringe adapter sleeve and a syringe adapter plunger including a first end slidably disposed within the syringe adapter sleeve and a second end extending from the syringe adapter sleeve. A syringe adapter needle is connected to the first end of the syringe adapter plunger and fluidly connectable to the first container through the syringe adapter plunger. The syringe adapter plunger has a first position wherein the syringe adapter needle is disposed within the syringe adapter sleeve and a second position where a portion of the syringe adapter needle extends from the syringe adapter sleeve. A vial adapter assembly is fluidly connectable to a second container and configured to slidably receive a portion of the syringe adapter sleeve of the syringe adapter assembly. The vial adapter assembly includes a transfer adapter sleeve, a shuttle valve slidably disposed within the transfer adapter sleeve, and a transfer adapter needle connected to the shuttle valve. The transfer adaptor needle is fluidly connectable to the second container through the shuttle valve, and the shuttle valve has a first position wherein the transfer adapter needle is disposed within the transfer adapter sleeve and is not in fluid communication with the second container, and a second position wherein the transfer adapter needle extends from the transfer adapter sleeve and is in fluid communication with the second container.
Patent NZ-591332-A (NZ)
Title: Method for manufacturing a stator for an energy converting apparatus with stator windings which increase in cross-sectional area radially outwards
Inventor: STIESDAL HENRIK
IPC: H02K15/04
Filed: 2011-02-23
Abstract: Disclosed is a method for manufacturing a stator for an energy converting apparatus. The method includes the steps of: - forming a support structure having an annular shape around an axial direction; - forming a first protrusion coupled to the support structure and extending radially; - forming, spaced apart from the first protrusion in a circumferential direction, a second protrusion coupled to the support structure and extending radially; - forming a plurality of first layers of a first wire; - arranging the plurality of first layers of the first wire between the first protrusion and the second protrusion. The forming and the arranging the plurality of first layers of the first wire is performed such that a circumferential extent of a cross-sectional area of the first wire increases radially outwards. The forming the first layers and/or the second layers includes bending the first wire and/or the second wire around an auxiliary structure plural times such that segments of the first wire and/or the second wire are stacked on top of each other and then bending the first wire and/or the second wire around the auxiliary structure at a different position plural times such that segments of the first wire and/or the second wire are stacked on top of each other.
Patent NZ-594586-A (NZ)
Title: Surface composition and method of application
Inventor: BEALE LEW
IPC: E04H4/00
Filed: 2010-02-23
Abstract: Disclosed herein is a method of manufacturing a surface composition for reducing degradation and fading of surfaces subjected to extended periods of submersion in an aqueous liquid, the method comprising applying at least one under layer to a suitable surface, permitting the under layer to cure and subsequently applying at least one clear unpigmented barrier layer; wherein the at least one underlayer comprises one or more polyesters, vinyl esters or terephthalate based resins; wherein the at least one underlayer comprises inorganic or organic pigments; wherein the clear unpigmented barrier layer is a polyester ge1coat comprising one or more phthalate containing polyesters, vinyl containing polyesters or methyl methacrylate containing polyesters; and wherein the clear unpigmented barrier layer is in use, disposed atop the under layer and in contact with the aqueous liquid, whereby the clear unpigmented barrier layer protects the structure and appearance of the under layer.
Patent NZ-595063-A (NZ)
Title: Polypeptides from neisseria meningitidis
Inventor: RAPPUOLI RINO
IPC: C07K14/22
Filed: 2007-06-29
Abstract: Disclosed is an isolated or recombinant polypeptide comprising an amino acid sequence that has at least 75% sequence identity to SEQ ID NO: 38, as defined in the complete specification. Also disclosed is the use of said polypeptide in the manufacture of a medicament or vaccine for treating or preventing disease and/or infection caused by Neisseria meningitides.
Patent NZ-598587-A (NZ)
Title: Coating composition including fluorescent material for producing secure images
Inventor: HEILMAN KEVIN L
IPC: G03G13/00
Filed: 2010-10-18
Abstract: A coating composition, system, and method for printing documents that are difficult to chemically or physically forge and that are easy to visually verify are disclosed. The system includes a substrate, a toner, including a colorant and a dye, a coating including fluorescent material, e.g., a primary migration-enhancing coating, applied using an offset printing process and optionally a secondary migration-enhancing coating applied using an offset printing process. An image formed using the toner of the invention is readily verified by comparing a colorant-formed image and a dye-formed image and/or to a reverse negative imaged formed by the dye quenching the fluorescent material. In addition, if a solvent is used in an attempt to alter the printed image on the substrate, the dye migrates or diffuses to indicate tampering with the document.
Patent NZ-603938-A (NZ)
Title: Conjugated blood coagulation factor viia
Inventor: HENRY WILLIAM
IPC: A61K38/36
Filed: 2011-04-28
Abstract: 603938 Discloses a factor VIIa-polyethylene glycol conjugate, wherein one or more polyethylene glycol groups are conjugated to FVIIa by a linker group bridging the sulphur atoms of two cysteine residues that formed a disulphide bond in FVIIa. Also, discloses the use in a composition for reducing the risk of hemarthrosis, haemorrhage, gastrointestinal bleeding and menorrhagia.
Patent NZ-609469-A (NZ)
Title: Improved high concentration anti-tnfα antibody liquid formulations
Inventor: NEU MICHAEL
IPC: A61P19/02
Filed: 2011-11-11
Abstract: Disclosed is a liquid aqueous formulation comprising adalimumab, a polysorbate; and less than 50 mg/ml of mannitol or sorbitol; wherein the formulation has a pH of 4.7 to 5.7 and does not contain a buffer and a salt, and a) wherein either injection of the formulation into a human subject results in a Pain Visual Analog Scale (VAS) score of less than 1.0 or injection of the formulation reduces pain associated with the injection in a human subject by at least about 50% when compared to injection of an otherwise identical formulation that comprises a salt and/or a buffer; or b) wherein the formulation has a characteristic selected from the group consisting of: i) a conductivity of less than about 2 mS/cm; ii) a hydrodynamic diameter (Dh) which is at least about 50% less than the Dh of the protein in a buffered solution at a given concentration; and iii) a hydrodynamic diameter (Dh) of less than about 4 nm.
Patent NZ-619163-A (NZ)
Title: Separation process
Inventor: MARSHALL EDWARD LESLIE
IPC: C12P41/00
Filed: 2012-07-16
Abstract: A process for treating a mixture of R,R- and S,S- lactide is provided. The process involves contacting the mixture with an aliphatic alcohol and an enzyme to produce a mixture comprising aliphatic ester of lactic acid corresponding to one lactide enantiomer and the aliphatic ester of lactyllactic acid corresponding to the other lactide enantiomer; separating the mixture from the enzyme, and recycling the enzyme to the process; and separating the aliphatic ester of lactic acid from the aliphatic ester of lactyllactic acid by fractional distillation. Also provided are processes for the production of S-lactic acid, S,S- lactide, poly-S-lactic acid, R-lactic acid, R,R-lactide, poly-R-lactic acid and stereocomplex polylactic acid.
Patent NZ-619582-A (NZ)
Title: Fluid portion dispenser
Inventor: NICHOLS ROSS WILLIAM
IPC: B67C3/20
Filed: 2012-07-03
Abstract: The disclosure relates to dispensers of fluids such as liquids, powders or particulate solids and in particular, relates to apparatus to quickly, hygienically and accurately dispense predetermined measures of fluid products into a vessel according to the capacity of the vessel. In the preferred embodiment there is provided a fluid portion dispenser (1) comprising at least one fluid reservoir, one or more nozzles (2), and a pump unit (5). Each nozzle being fixed to a work surface and having a nozzle outlet configured to dispense fluid from. The pump unit connecting each reservoir (7) to a nozzle and configured to pump fluid from each reservoir to a nozzle. Wherein each nozzle includes an activation mechanism, adapted to identify the capacity of a vessel in association with a nozzle outlet and activate the pump unit to dispense a portion of fluid from the nozzle outlet according to the capacity of the vessel identified. The actuation mechanism may measure the diameter or the height of a vessel to determine the capacity. The dispenser may comprise a digital processor and memory configured or programmed to control the pump. The reservoir may be configured to control the temperature of the fluid.
Patent NZ-626771-A (NZ)
Title: A float valve
Inventor: COLLINS PHILIP JOHN
IPC: F16K31/18
Filed: 2014-06-27
Abstract: A valve assembly for use in a water tank or trough is disclosed. The valve assembly has an actuating arm (91) pivotally coupled to the valve with a pivot coupling defining an axis of rotation. The actuating arm moves between a first pivotal position and a second pivotal position to open and close the valve. The actuating arm includes a weakened portion (120) intermediate of its length having a lower resistance to bending of the arm in a plane substantially orthogonal to the axis of rotation of the arm and dimensioned. This allows the arm to be relatively easily manually bent at the weakened portion by an installer or during the life of the valve, to adjust the liquid/water height at which the valve opens and closes.
Patent NZ-628009-A (NZ)
Title: Use of modafinil in the treatment of cocaine addicts
Inventor: SUPLIE PASCAL
IPC: A61P25/36
Filed: 2013-02-25
Abstract: Disclosed is the use of modafinil (2-[(diphenylmethyl)sulfinyl)]acetamide) prepared from supercritical carbon dioxide (CO2) in the dextrorotatory enantiomer form (modafinil S) with increased dissolution and bioavailability (relative to racemic form) for treating cocaine addiction. The pharmacokinetic features of the modafinil is characterised as having a rapid release time of less than 1 hour and reduced wakefulness-promoting effects of less than 4 hours. The modafinil is to be taken in the form of a pharmaceutical composition via oral administration, each unit dose comprising 25-200 mg of modafinil S.
Patent NZ-631054-A (NZ)
Title: A catheter system
Inventor: PETER HEBBARD
IPC: A61M25/01
Filed: 2014-03-12
Abstract: A catheter system including a catheter (10) and a stylet (30). The stylet includes an elongate portion (31) and a shaped portion (32). The elongate portion is receivable within the catheter. The elongate portion and the catheter are co-operably configured such that, when the elongate portion is so received, at least a portion of the elongate portion is spaced from the catheter such that the at least portion and the catheter together define at least one elongate void for conveying fluid along the catheter at least one of to or from one or more sites within a patient. The shaped portion is positioned to be within the patient.
Patent NZ-700340-A (NZ)
Title: Lentiviral vector particles having improved transduction efficiency for cells expressing dc- sign
Inventor: NICOLAI CHRISTOPHER JAMES
IPC: C12N15/867
Filed: 2013-03-29
Abstract: A method of generating a pseudotyped lentiviral vector particle comprising: (a) culturing in a culture medium comprising kifunensine a virus packaging cell comprising: (1) a lentiviral vector genome comprising an exogenous polynucleotide of interest, (2) a polynucleotide encoding a Sindbis E2 glycoprotein that preferentially binds dendritic cells expressing DCSIGN, and (3) a polynucleotide encoding a Vpx protein or a Vpr protein that retains SAMHD1-inhibiting activity; and (b) isolating a pseudotyped lentiviral vector particle that preferentially binds dendritic cells expressing DC-SIGN, and compositions thereof.
Patent NZ-702367-A (NZ)
Title: Use of multi-stage polymerizate dispersions to coat metal sheets
Inventor: JAHNS EKKEHARD
IPC: E04D13/00
Filed: 2013-06-04
Abstract: The invention relates to the use of aqueous multi-stage polymerizate dispersions, which can be obtained by radically initiated aqueous emulsion polymerization, having a soft phase and a hard phase and a stage ratio of hard to soft of 25 to 95 wt% to 75 to 5 wt%, wherein the glass transition temperature (Tg) of the soft phase as the first stage is -30 to 0 °C and the glass transition temperature of the hard phase as the second stage is 20 to 60 °C, containing at least one monomer of general formula (I) in which the variables have the following meaning: n = 0 to 2, R1, R2, R3 = hydrogen or a methyl group independently of each other, X = O or NH, Y = H, alkali metal, NH4, to coat metal sheets.